Pfizer (PFE), Lilly (LLY) Announce Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Go back to Pfizer (PFE), Lilly (LLY) Announce Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Eli Lilly & Co. (LLY), Vir Biotech (VIR) & GlaxoSmithKline (GSK) Report Positive Topline Data from Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

March 29, 2021 8:32 AM EDT

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p 5.27; cycle threshold value

In addition, bamlanivimab administered with VIR-7831... More